Prescriptions – News Journos

Study Reveals Quick Medication Prescriptions for Young Children Diagnosed with ADHD

News Editor — Tue, 09 Sep 2025 00:44:54 +0000

This article is published by News Journos

A recent investigation by Stanford Medicine has unveiled concerning trends in the prescription of medication for young children diagnosed with attention-deficit/hyperactivity disorder (ADHD). Released on Friday, the study reveals that a significant number of preschool-aged children, specifically those aged 3 to 5, are often prescribed ADHD medications much too quickly following their diagnosis. The findings, published in JAMA Network Open, indicate a shift towards medication rather than behavioral interventions, prompting a call for further scrutiny of current treatment practices.

Article Subheadings
1) Understanding ADHD in Young Children
2) Medication Trends Post-Diagnosis
3) Side Effects and Treatment Efficacy
4) The Importance of Behavioral Interventions
5) Conclusions from the Study

Understanding ADHD in Young Children

Attention-deficit/hyperactivity disorder, or ADHD, is a neurodevelopmental disorder that affects children’s ability to focus, control their impulses, and regulate their behavior. Children with ADHD often exhibit excessive energy levels, making it difficult for them to sit still or pay attention effectively. According to Dr. Jamie Howard, a senior clinical psychologist at the Child Mind Institute, ADHD is typically characterized by behaviors such as impulsivity, hyperactivity, and inattentiveness. The disorder can manifest in various ways, leading to challenges at both home and school.

In young children, diagnosing ADHD can be particularly complex due to the overlapping characteristics that normal developmental behavior can share with ADHD symptoms. Moreover, ADHD is believed to affect a significant portion of preschool-age children, with recent estimates indicating that it is prevalent in 5% to 10% of this age group. The understanding of ADHD has evolved, leading to a greater emphasis on early identification and intervention. However, this has raised concerns about the reliance on medications as a first-line treatment, as discussed in the Stanford study.

Medication Trends Post-Diagnosis

The Stanford Medicine study analyzed the health records of nearly 10,000 preschool-aged children diagnosed with ADHD between 2016 and 2023. Alarmingly, it was found that about 68% of these children were prescribed medications, primarily stimulants like Ritalin, before reaching the age of 7. Stimulants are known to help improve attention spans and emotional regulation in many patients but pose risks, particularly when prescribed to very young children. The study indicated that a substantial proportion—42%—of these children received a prescription within 30 days of their initial diagnosis. This quick transition raises questions about the appropriateness of bypassing alternative treatments.

The researchers highlighted that while medications like Ritalin can be effective, there is a growing concern about the child’s overall treatment journey prior to being medicated. The quick accessibility to pharmaceutical solutions might overshadow the potential benefits of implementing a broader treatment strategy that focuses on behavioral therapies first.

Side Effects and Treatment Efficacy

Despite the benefits of medications for some children, they are not without risks. According to Dr. Yair Bannett, an assistant professor of pediatrics at Stanford Medicine and lead author of the study, potential side effects include irritability, aggressive behavior, and various emotional issues. The study acknowledges the age-related concerns surrounding medication’s toxicity in children aged four to five; however, the likelihood of treatment failure remains a critical factor. Families often weigh the side effects of these medications against their perceived benefits, and many choose to discontinue treatment—indicating a possible disconnect between the initial diagnosis and long-term treatment success.

The statistics revealed in this study prompt an urgent need for a review of medical practices. When such a large percentage of young children are quickly moved to medication without a thorough exploration of other treatment options, it suggests a potential gap in adherence to best clinical practices. It raises significant implications for parents, educators, and clinicians alike regarding the delicate balance of treatment approaches.

The Importance of Behavioral Interventions

Experts like Dr. Howard advocate for the initial use of behavioral interventions as the preferred treatment pathway for young children diagnosed with ADHD. These strategies can include behavior modification techniques, parent training, and supporting children in developing coping skills that can reduce impulsive behaviors and improve attention. Dr. Howard emphasizes the philosophy of starting treatment with the “lowest possible harm” through behavioral methods before resorting to medication.

Such behavioral approaches often carry lower risks compared to introducing stimulants and can lead to better long-term outcomes. Implementing these strategies requires the support of parents, teachers, and clinicians. The emphasis on collaboration in developing customized treatment plans reflects a growing recognition of the need to treat children holistically rather than merely focusing on symptoms.

Conclusions from the Study

The Stanford study ultimately calls for further investigation into the rapid prescription rates of ADHD medications among preschool-aged children. The researchers noted that with approximately 76% of those diagnosed being boys, there may be potential gender biases influencing diagnosis and treatment practices. The study highlights a pressing concern that the current medical frameworks may not adequately address the complexities surrounding ADHD in early childhood.

In summation, the findings urge both parents and healthcare providers to consider the broader implications of early medication, potential side effects, and the necessity for a more thorough evaluation of treatment paths that prioritize behavioral strategies over immediate pharmacological intervention. The study opens the floor for further discussions on ADHD, its treatment protocols, and the importance of tackling mental health in young children with a careful and informed approach.

No.	Key Points
1	Study shows that ADHD medications are often prescribed to preschoolers too quickly.
2	68% of diagnosed children received prescriptions before age 7, with 42% within 30 days of diagnosis.
3	Potential side effects include irritability, aggressiveness, and emotional issues.
4	Experts advocate starting treatment with behavioral interventions instead of medication.
5	Further investigation is necessary to understand treatment appropriateness and patterns.

Summary

The findings from the recent Stanford study indicate a pressing need for a reconsideration of ADHD treatment protocols in young children. With many children receiving medications quickly after diagnosis, there is an opportunity to prioritize behavioral interventions first. This approach could lead to improved outcomes and a better overall understanding of ADHD management at an early age. The study’s insights encourage professionals to reflect on current practices and adopt a more balanced approach that considers both the immediate and long-term effects of treatment strategies.

Frequently Asked Questions

Question: What is ADHD?

ADHD, or attention-deficit/hyperactivity disorder, is a neurodevelopmental disorder impacting children’s attention, behavior, and ability to regulate impulses.

Question: Why are medications prescribed quickly after a diagnosis?

The study suggests that there is a tendency among healthcare providers to prescribe medications promptly without fully considering behavioral interventions, which could be more appropriate for young children.

Question: What are some common side effects of ADHD medications?

Common side effects of ADHD medications can include irritability, mood swings, and aggressive behavior, which may lead families to discontinue treatment if the side effects outweigh perceived benefits.

Online Buyers Bypass Prescriptions for Ozempic Weight Loss Solutions

News Editor — Thu, 05 Jun 2025 08:05:40 +0000

This article is published by News Journos

In an age characterized by the pursuit of speed, the quickening trend of using prescription diabetes medications for weight loss poses urgent questions for global health. Amid rising obesity rates and the increasing popularity of medications like Ozempic and Mounjaro, concerns are mounting regarding improper use of these drugs for aesthetic aims. Health experts warn that this could lead to significant health crises exacerbated by the ease of access to these prescriptions through unregulated channels.

Article Subheadings
1) The Rise of Rapid Weight Loss Trends
2) Understanding GLP-1 Medications
3) The Dangers of Misuse and Counterfeiting
4) Regulatory Gaps and Consumer Protection
5) The Societal Implications of Fast Fixes

The Rise of Rapid Weight Loss Trends

The demand for quick weight loss solutions has surged in recent years, driven by societal pressures for a leaner appearance. This phenomenon places a spotlight on prescription medications initially designed to treat medical conditions. With over 1 billion people suffering from obesity globally and more than 830 million managing diabetes, anxiety about health conditions has prompted many to seek shortcuts. Drugs like Ozempic and Mounjaro, originally crafted for diabetes management, have become a popular choice among individuals looking to shed extra pounds quickly.

The use of these medications for weight loss is not solely limited to those afflicted with obesity. Instead, a growing number of health-conscious individuals, often with no underlying medical conditions, are opting to use these drugs to achieve aesthetic goals. This trend highlights a cultural shift that places appearance over health, raising red flags among medical professionals concerned about the ramifications.

Understanding GLP-1 Medications

GLP-1 medications, which include drugs like Ozempic, Wegovy, and Mounjaro, are designed to assist in the regulation of blood sugar levels and appetite. They work by mimicking the action of a hormone that targets areas of the brain involved in appetite regulation. For patients with obesity and diabetes, these drugs can result in substantial weight loss—up to 15% of body weight—making them valuable tools for managing weight-related health issues.

However, the enticing side effects of these drugs have attracted a demographic interested primarily in aesthetics rather than health management. Such motivations raise ethical concerns about the misuse of medical advancements. While these medications can indeed facilitate weight loss, experts emphasize the importance of using them under medical supervision, especially given the potential risks and side effects involved.

The Dangers of Misuse and Counterfeiting

The trend towards the off-label use of GLP-1 drugs invites a range of health complications. Individuals using these drugs without medical oversight may experience side effects such as nausea, vomiting, and diarrhea, posing additional health risks. Serious complications can arise, including pancreatitis and kidney injuries, especially when the drugs are used in conjunction with other medications.

Moreover, the rise in illicit online sales of these medications serves as a conduit for counterfeit drugs. Reports from authorities indicate that counterfeit versions of Ozempic have been found to contain incorrect substances, leading to hospitalizations. The World Health Organization has issued alerts regarding falsified versions of these medications that have circulated in multiple countries, emphasizing the grave risks posed by unregulated access to such prescriptions.

Regulatory Gaps and Consumer Protection

Despite recognizing the dangers of improper medication use, regulatory bodies are struggling to keep pace with the evolving landscape of online commerce. A multitude of websites allows for the digital purchase of these drugs without sufficient medical consultation, often leading individuals to bypass necessary health screenings and consultations. This has created a gray market where safe usage guidelines are not enforced.

Governments and regulatory authorities are beginning to take notice. For example, the European Commission’s Digital Services Act mandates platforms to address the risks associated with illegal content. Users must have the ability to report dubious products, and online marketplaces are required to ensure traceability in order to monitor compliance. Yet many believe these measures remain insufficient in a digital landscape characterized by rapid change and minimal oversight.

The Societal Implications of Fast Fixes

The proliferation of quick-fix weight-loss solutions extends beyond individual health concerns; it represents a larger societal issue regarding self-image and health responsibilities. The normalization of using prescription drugs for aesthetic aims may inadvertently erode the emphasis on traditional health practices such as diet and exercise. It diminishes the conversation surrounding healthy living, particularly for younger, impressionable individuals who seek validation and acceptance through appearance.

Furthermore, this trend perpetuates a cycle of dependency on pharmaceutical solutions rather than fostering a holistic approach to health. As health professionals navigate the complexities of treatment recommendations, they face an uphill battle against pervasive misinformation, social media influences, and a culture increasingly predisposed to betting on shortcuts rather than long-term solutions.

No.	Key Points
1	The rise in popularity of weight-loss drugs has spurred concerns over ethical medical use.
2	GLP-1 medications can cause significant weight loss but should only be used under supervision.
3	Counterfeit drugs present dangerous risks, further complicating patient safety.
4	Regulatory bodies struggle to keep up with the unregulated online drug sales market.
5	Societal implications surround dependence on pharmaceuticals for aesthetic purposes.

Summary

The rush towards rapid weight loss has brought to light a complex web of ethical, health, and regulatory issues surrounding the use of prescription drugs like Ozempic and Mounjaro. While these medications offer legitimate benefits for managing obesity and diabetes, the burgeoning trend of their misuse for aesthetic purposes poses serious health risks. As the situation evolves, it is imperative for both health authorities and tech companies to enforce stricter controls to safeguard consumer health and ensure that medical advancements are used appropriately and responsibly.

Frequently Asked Questions

Question: What are GLP-1 medications?

GLP-1 medications are drugs designed to regulate blood sugar levels and reduce appetite for patients with type 2 diabetes and obesity. They mimic a hormone involved in appetite regulation to help users lose weight.

Question: Why are these medications being misused?

The misuse of GLP-1 medications for weight loss stems from societal pressures to maintain a lean physique. Many individuals choose to use these drugs without medical necessity, hoping for quick results without engaging in traditional diet and exercise.

Question: What are the risks associated with misusing these medications?

Misuse of GLP-1 medications can lead to various side effects, such as nausea and vomiting. Serious complications may include pancreatitis and kidney damage, particularly when used without medical supervision.

FDA to Restrict Fluoride Prescriptions for Children Amid Growing Health Concerns

News Editor — Tue, 13 May 2025 21:10:44 +0000

This article is published by News Journos

On Tuesday, the Food and Drug Administration (FDA) announced significant measures aimed at protecting children’s health by initiating the removal of unapproved ingestible fluoride prescription drug products for kids. This decision aligns with the ongoing efforts of the Health and Human Services Department to eliminate outdated medical practices that may pose risks to developing children. Experts warn that these unapproved products, previously prescribed to infants and toddlers, could negatively impact their health in various ways, including potential alterations to gut microbiomes and developmental issues.

Article Subheadings
1) Background of Fluoride Use
2) Health Risks Associated with Ingestible Fluoride
3) Regulatory Measures and Future Actions
4) Public and Political Reactions
5) Shift in National Policies Towards Fluoride

Background of Fluoride Use

Fluoride has long been a common component in dental care, utilized mainly for its ability to strengthen teeth and reduce the incidence of cavities. This mineral is often added to public water supplies, toothpaste, and dental treatments. In the United States, fluoride’s role in oral health has been widely endorsed by dental professionals; however, concerns have begun to surface more recently regarding its long-term effects, especially on young children. Historically, some medical practitioners prescribed fluoride supplements in the form of tablets to high-risk children, believing this would bolster their dental health.

Health Risks Associated with Ingestible Fluoride

Recent statements from the FDA highlight the adverse effects associated with ingestible fluoride products. According to officials, these products have not received FDA approval and may present significant health risks, particularly among developing children. Chief among the concerns is the potential harm to the gut microbiome, a complex ecosystem of microorganisms crucial for digestive and overall health. Additionally, studies have raised questions about links between fluoride exposure and disorders such as thyroid dysfunction, weight gain, and cognitive decline.

The health implications have prompted key figures within health organizations to advocate for a reevaluation of fluoride use, particularly in pediatric cases. For instance, health advocates argue that children should avoid potential sugar excesses to prevent cavities through good dietary practices rather than relying on ingestible fluoride products that may negatively affect their microbiomes.

Regulatory Measures and Future Actions

In response to these health risks, the FDA has begun taking steps to remove concentrated ingestible fluoride prescription products from the market. Health and Human Services Secretary has emphasized the importance of ensuring that the health and safety of children are prioritized in public health policies. Nixon announced that HHS, along with the FDA, would conduct a comprehensive safety review involving public input, with the aim of finalizing guidelines by the end of October. This review is intended to provide parents and the medical community with the information necessary to make informed choices regarding fluoride exposure for their children.

Public and Political Reactions

The move to eliminate ingestible fluoride products has drawn diverse reactions from the public and political figures. While many parents and health advocates welcome the FDA’s actions as a necessary step towards safeguarding children’s health, others express concerns about the implications for dental health. Critics, including local dental professionals, argue that such a ban could detrimentally affect children who require fluoride for cavity prevention, particularly in communities facing significant dental health issues.

Political figures such as Florida Governor Ron DeSantis have also taken firm stances against fluoride additives in public water systems, framing them as a form of “forced medication,” a viewpoint shared by various factions within the population. The debate surrounding fluoride, particularly in public health conversations, has become emblematic of larger discussions about parental rights, informed consent, and government regulations on health practices.

Shift in National Policies Towards Fluoride

The recent statements from the FDA and HHS mark a substantial shift in national policies regarding the use of fluoride in children’s health care. Historically accepted as a standard preventive measure in dental health, fluoride’s role is now under intense scrutiny. The decision to reassess its use for infants and toddlers aligns with a growing trend where states like Utah and Florida have enacted legislation prohibiting fluoride additives in drinking water.

This evolving landscape not only reflects changing attitudes towards public health interventions but may also signal a larger transformation in how health decisions are made in America. As health authorities work to establish new guidelines, the dialogue between public health and individual choice will likely become increasingly prominent in the national conversation surrounding fluoride.

No.	Key Points
1	The FDA is initiating the removal of unapproved ingestible fluoride products for children from the market.
2	Health officials warn that these products pose risks including gut microbiome alteration and potential developmental issues.
3	HHS and the FDA are set to conduct a comprehensive safety review, gathering public input for new guidelines.
4	The decision has garnered mixed reactions, highlighting concerns about dental health among children.
5	Ongoing legislative changes in states are reshaping public perceptions and policies concerning fluoride use.

Summary

The FDA’s recent announcement to remove unapproved ingestible fluoride prescription products marks a pivotal moment in public health policy, particularly concerning children’s health. With health risks associated with these products coming to light, officials are taking bold actions to safeguard children from potentially harmful substances. This move not only reflects an ongoing reconsideration of fluoride’s role in healthcare but also mirrors broader societal conversations about health autonomy and informed consent.

Frequently Asked Questions

Question: What prompted the FDA’s decision to remove ingestible fluoride products?

The FDA’s decision was prompted by concerns over unapproved ingestible fluoride products for children posing potential health risks.

Question: How does ingestible fluoride differ from topical fluoride?

Ingestible fluoride is consumed orally, such as in the form of tablets, whereas topical fluoride is applied directly to the teeth in products like toothpaste.

Question: What are the new guidelines expected to address?

The new guidelines are anticipated to focus on promoting safe and effective dental hygiene practices without compromising gut health or children’s overall well-being.

Walgreens Agrees to $300 Million Settlement Over Invalid Opioid Prescriptions

News Editor — Tue, 22 Apr 2025 11:18:51 +0000

This article is published by News Journos

Walgreens Boots Alliance has reached a substantial settlement of $300 million in response to allegations that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances. The U.S. Justice Department, alongside other federal agencies, claims that for over a decade, Walgreens pharmacists filled questionable prescriptions, disregarding established legal obligations and protocols. This settlement comes amidst a broader national crisis concerning opioid misuse, which has resulted in significant loss of life and health complications across the country.

Article Subheadings
1) Allegations Against Walgreens
2) Details of the Settlement
3) The Opioid Crisis Context
4) Walgreens’ Response
5) Implications of the Settlement

Allegations Against Walgreens

The allegations against Walgreens are rooted in a comprehensive investigation by the U.S. Justice Department over the last decade, centering on illegal prescription practices. Officials assert that within its pharmacy network, Walgreens enabled the distribution of millions of prescriptions for opioids and other controlled substances. Key accusations spotlight how pharmacists allegedly filled these prescriptions with clear signs of irregularities, such as discrepancies in patient information and prescription authorizations.

The Justice Department’s complaint lays out the assertion that Walgreens officials not only ignored these critical warning signs but also exerted pressure on pharmacy staff to expedite the filling process, often sidelining proper verification procedures. This systemic negligence supposedly facilitated the illegal flow of opioids into communities, exacerbating the nationwide epidemic of opioid misuse.

Details of the Settlement

As part of the settlement, Walgreens will deposit $300 million to address the claims made against it for the unlawful distribution of controlled substances. This agreement, reached on a date undisclosed in the initial reports, includes the dismissal of the Justice Department’s complaints regarding the alleged violations, which primarily fell under the Controlled Substances Act (CSA) and the False Claims Act (FCA).

The implications of this settlement are far-reaching. Had the case proceeded to trial and Walgreens found liable, the pharmacy chain could have faced substantial fines for each violation, potentially amounting to tens of millions of dollars. By settling, Walgreens avoids the protracted legal battle and significant financial risk associated with a court judgment against them.

The Opioid Crisis Context

The backdrop of this case is a devastating public health crisis. More than 700,000 Americans have succumbed to opioid overdoses since 1999, according to the Centers for Disease Control and Prevention (CDC). The opioid epidemic has been exacerbated by overprescription and illegal distribution, making the role of pharmacies, like Walgreens, critically scrutinized by health officials and law enforcement alike.

Opioids have infiltrated the medical and social fabric of the U.S., leading to increased addiction rates, widespread dependence on prescription medications, and tragic outcomes. In light of these statistics, the Justice Department’s actions reflect a vigorous federal response to regulate and monitor pharmacies involved in the distribution of these hazardous substances.

Walgreens’ Response

In response to the allegations and subsequent settlement agreement, Walgreens officials have emphasized their disagreement with the government’s assertions. A spokesperson stated, “We strongly disagree with the government’s legal theory and admit no liability.” They underscored that Walgreens pharmacists are committed healthcare professionals dedicated to patient safety.

The company reiterates its efforts to educate both staff and the public on combatting opioid misuse and promoting safe usage of prescription medications. As a part of its mission, Walgreens claims to have instituted various measures to safeguard against illegal prescription practices, which they assert demonstrate their dedication to public health and compliance.

Implications of the Settlement

The implications of Walgreens’ settlement extend beyond the immediate financial consequences. It highlights the ongoing struggles faced by pharmacies across the nation as they attempt to balance patient care with regulatory compliance. The settlement serves as a cautionary tale not only for Walgreens but for other healthcare providers operating within the pharmaceutical realm.

Further, this case has stirred discussions regarding the responsibilities of pharmacies and healthcare professionals in managing prescriptions for highly addictive medications. It beckons a deeper examination of existing policies and practices, pushing for reforms that ensure patient safety and responsible prescribing habits within the pharmacy industry.

No.	Key Points
1	Walgreens has settled for $300 million over allegations of unlawful prescription fillings.
2	The U.S. Justice Department claims Walgreens pharmacists filled questionable opioid prescriptions for over a decade.
3	The opioid crisis has resulted in over 700,000 deaths in the U.S. since 1999, highlighting the severity of the epidemic.
4	Walgreens officials dispute the claims and assert the commitment of pharmacists to patient safety.
5	The settlement raises questions about regulatory practices and the responsibilities of pharmacies regarding prescriptions.

Summary

In conclusion, Walgreens’ settlement of $300 million settles serious allegations regarding the filling of invalid prescriptions for opioids, reflecting the broader challenges in the fight against the opioid epidemic. As the company moves forward, the pharmacy industry as a whole must learn from these events and strengthen measures to combat unauthorized prescription practices. This case not only signifies accountability but also serves as a call to action for enhanced regulations aimed at protecting public health.

Frequently Asked Questions

Question: What led to the $300 million settlement for Walgreens?

The settlement arose from allegations that Walgreens unlawfully filled millions of invalid prescriptions for opioids and other controlled substances, violating the Controlled Substances Act.

Question: How has the opioid crisis affected the U.S. population?

The opioid crisis has had a devastating impact, resulting in over 700,000 deaths in the U.S. since 1999, directly linked to opioid overdoses and misuse.

Question: What is Walgreens’ stance regarding the allegations?

Walgreens has stated that they strongly disagree with the legal claims made against them and assert that their pharmacists are dedicated health care professionals committed to patient safety.